| Literature DB >> 28988825 |
Sylvia Andrzejewski1, Eva Klimcakova2, Radia M Johnson2, Sébastien Tabariès2, Matthew G Annis2, Shawn McGuirk1, Jason J Northey2, Valérie Chénard1, Urshila Sriram1, David J Papadopoli1, Peter M Siegel3, Julie St-Pierre4.
Abstract
Metabolic adaptations play a key role in fueling tumor growth. However, less is known regarding the metabolic changes that promote cancer progression to metastatic disease. Herein, we reveal that breast cancer cells that preferentially metastasize to the lung or bone display relatively high expression of PGC-1α compared with those that metastasize to the liver. PGC-1α promotes breast cancer cell migration and invasion in vitro and augments lung metastasis in vivo. Pro-metastatic capabilities of PGC-1α are linked to enhanced global bioenergetic capacity, facilitating the ability to cope with bioenergetic disruptors like biguanides. Indeed, biguanides fail to mitigate the PGC-1α-dependent lung metastatic phenotype and PGC-1α confers resistance to stepwise increases in metformin concentration. Overall, our results reveal that PGC-1α stimulates bioenergetic potential, which promotes breast cancer metastasis and facilitates adaptation to metabolic drugs.Entities:
Keywords: PGC-1α; breast cancer; metabolic flexibility; metabolomics; metastasis; metformin; mitochondria; phenformin; respirometry; seahorse
Mesh:
Substances:
Year: 2017 PMID: 28988825 DOI: 10.1016/j.cmet.2017.09.006
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287